Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).

被引：1
|
作者：
Krantz, Benjamin A.
Tsui, Dana
Lowery, Maeve Aine
Capanu, Marinela
Yu, Kenneth H.
Kelsen, David Paul
Gedvilaite, Erika
Zhang, Liguo
Selcuklu, S. Duygu
You, Daoqi
Pernicka, Jennifer S. Golia
Do, Richard K. G.
Iacobuzio-Donahue, Christine A.
O'Reilly, Eileen Mary
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Trinity Coll Dublin, Dublin, Ireland
[3] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
316
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CD73 role in pancreatic ductal adenocarcinoma (PDAC)
    Katsuta, Eriko
    Okubo, Naoki
    Tsuyuki, Sho
    Kobayashi, Noritoshi
    Ichikawa, Yasushi
    CANCER SCIENCE, 2025, 116 : 833 - 833
  • [42] Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
    Shao, Huilin
    Zhang, Yue
    Yan, Jie
    Ban, Xinchao
    Fan, Xiaojie
    Chang, Xiaoyan
    Lu, Zhaohui
    Wu, Yan
    Zong, Liju
    Mo, Shengwei
    Yu, Shuangni
    Chen, Jie
    ONCOTARGETS AND THERAPY, 2021, 14 : 2163 - 2175
  • [43] MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
    Prinz, Christian
    Fehring, Leonard
    Frese, Robin
    CELLS, 2022, 11 (15)
  • [44] Allelic ratio of KRAS mutations in pancreatic ductal adenocarcinoma
    Lennerz, Jochen K.
    Stenzinger, Albrecht
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Critical role of KRAS mutation in pancreatic ductal adenocarcinoma
    Fan, Zhiyao
    Fan, Kun
    Yang, Chao
    Huang, Qiuyi
    Gong, Yitao
    Cheng, He
    Jin, Kaizhou
    Liu, Chen
    Ni, Quanxing
    Yu, Xianjun
    Luo, Guopei
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 (06) : 1728 - 1736
  • [46] PATHOGENIC KRAS MUTATIONS PROFILE IN PANCREATIC DUCTAL ADENOCARCINOMA
    Iacob, Razvan
    Dima, Simona
    Sorop, Andrei
    Manea, Ioana
    Ionescu, Victor S.
    Spiridon, Andreea G.
    Stoica, Bianca
    Bunduc, Stefania
    Chiosa, Andrei
    Cazacu, Irina M.
    Croitoru, Vlad M.
    Chelaru, Raluca
    Iacob, Speranta
    Becheanu, Gabriel
    Dumbrava, Mona
    Herlea, Vlad
    Croitoru, Adina E.
    Csiki, Irma Eva
    Ceafalan, Laura C.
    Popescu, Irinel
    Gheorghe, Cristian
    GASTROENTEROLOGY, 2023, 164 (06) : S802 - S803
  • [47] Circulating levels of ADAM12, a stromal activation biomarker, are predictive of survival in pancreatic ductal adenocarcinoma (PDAC)
    van Laarhoven, H. W.
    Damhofer, H.
    Veenstra, V. L.
    Waasdorp, C.
    Van Rijssen, L. B.
    Dijk, F.
    Wilmink, J. W.
    Besselink, M. G.
    Busch, O. R.
    Medema, J. P.
    Li, J. Shiansong
    Jiang, R.
    Pierce, D. W.
    Bijlsma, M. F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
    Kim, Hongbeom
    Kang, Kyung Nam
    Shin, Yong Sung
    Byun, Yoonhyeong
    Han, Youngmin
    Kwon, Wooil
    Kim, Chul Woo
    Jang, Jin-Young
    CANCERS, 2020, 12 (06)
  • [49] PIK3CA mutations in pancreatic ductal adenocarcinoma (PDAC)
    Pitiyarachchi, O.
    Sim, H-W.
    ANNALS OF ONCOLOGY, 2024, 35 : S1499 - S1499
  • [50] Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)
    Pitiyarachchi, O.
    Lin, F. P.
    Spooner, A.
    Sharbeen, G.
    Barker, H. P.
    Thornton, K.
    Collignon, E.
    Ballinger, M. L.
    Thomas, D. M.
    Magenau, A.
    Porazinski, S.
    Raina, A.
    Sjoquist, K. M.
    Chantrill, L. A.
    Gebski, V.
    Sowmya, A.
    Timpson, P.
    Pajic, M.
    Goldstein, D.
    Phillips, P. A.
    ANNALS OF ONCOLOGY, 2024, 35 : S925 - S925
12345